Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Scopolamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 3/20 | 0.85 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.85 |
| ▸ | TSHR | P16473 | 3/20 | 0.85 |
| ▸ | LMNA | P02545 | 2/20 | 0.85 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.85 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.85 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.85 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.85 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.85 |
| ▸ | BLM | P54132 | 3/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.84 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.84 |
| ▸ | MEN1 | O00255 | 1/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.82 |
| ▸ | TP53 | P04637 | 1/20 | 0.82 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Scopolamine SCHEMBL892535 | 1.00 | CHRM4 (0.85) | CHRM4CHRM1TSHRLMNACHRM2 | |
| Scopolamine SCHEMBL892533 | 1.00 | CHRM4 (0.85) | CHRM4CHRM1TSHRLMNACHRM2 | |
| Scopolamine SCHEMBL22163750 | 0.95 | CHRM4 (0.91) | CHRM4CHRM1TSHRLMNACHRM2 | |
| Scopolamine SCHEMBL22163749 | 0.95 | CHRM4 (0.91) | CHRM4CHRM1TSHRLMNACHRM2 | |
| Scopolamine SCHEMBL31064233 | 0.95 | CHRM4 (0.91) | CHRM4CHRM1TSHRLMNACHRM2 | |
| Scopolamine SCHEMBL3717240 | 0.94 | CHRM4 (0.85) | CHRM4CHRM1TSHRLMNACHRM2 | |
| Scopolamine SCHEMBL23371689 | 0.92 | CHRM1 (1.00) | CHRM4CHRM1TSHRLMNACHRM2 | |
| Scopolamine SCHEMBL20754076 | 0.92 | CHRM1 (1.00) | CHRM4CHRM1TSHRLMNACHRM2 | |
| Scopolamine SCHEMBL22393238 | 0.92 | CHRM1 (1.00) | CHRM4CHRM1TSHRLMNACHRM2 | |
| Scopolamine SCHEMBL24175406 | 0.92 | CHRM1 (1.00) | CHRM4CHRM1TSHRLMNACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210145036-A1 | LIPOPHILIC ACTIVE AGENT INFUSED COMPOSITIONS WITH REDUCED FOOD EFFECT | Poviva Corp. | 2021-05-20 | — | — | US | disclosed |
| EP-2604256-B1 | Multi layer coatings | HEXAL AG (DE) | 2016-04-13 | — | — | EP | disclosed |
| EP-2604256-A1 | Multi layer coatings | Hexal AG (DE) | 2013-06-19 | — | — | EP | disclosed |
| US-20120082721-A1 | Enteric coating | H E X A L AKTIENGESELLSCHAFT (DE) | 2012-04-05 | — | — | US | disclosed |
| EP-2255794-A1 | Enteric coating | H e x a l Aktiengesellschaft (DE) | 2010-12-01 | — | — | EP | disclosed |
| US-20070166362-A1 | Transdermal and transmucosal preparations | KABUSHIKI KAISHA SANGI (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1797900-A1 | PREPARATION FOR PERCUTANEOUS/PERMUCOSAL ABSORPTION | KABUSHIKI KAISHA SANGI (JP) | 2007-06-20 | — | — | EP | disclosed |
| EP-1101490-B1 | PREPARATION CAPABLE OF RELEASING DRUG AT TARGET SITE IN INTESTINE | TANABE SEIYAKU CO (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-6638534-B1 | High speed release; coating of acrylic, maleic or polyvinyl polymer; inflammable bowel syndrome, Crohn*s disease | TANABE SEIYAKU CO., LTD. (JP) | 2003-10-28 | — | — | US | disclosed |
| EP-1101490-A1 | PREPARATION CAPABLE OF RELEASING DRUG AT TARGET SITE IN INTESTINE | TANABE SEIYAKU CO., LTD. (JP) | 2001-05-23 | — | — | EP | disclosed |
| US-4695465-A | ADMINISTERING DRUGS, ABSORPTION | TAKEDA CHEMICAL INDUSTRY, LTD. (JP) | 1987-09-22 | — | — | US | disclosed |
| EP-0159168-A2 | Soft patch drug preparation | Takeda Chemical Industries, Ltd. (JP) | 1985-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145036-A1 | LIPOPHILIC ACTIVE AGENT INFUSED COMPOSITIONS WITH REDUCED FOOD EFFECT | LIPC, PNLIP, LIPA | CHRM1 3961/4885CHRM4 4248/4885TSHR 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.